MRI-guided laser treatment for early prostate cancer

Trial details

Who runs it

University Health Network, Toronto

Trial code

NCT03650595

Record updated

5 June 2026

Original description

This clinical research study is designed to determine the ability of in bore MRI guided Focal Laser Ablation (MRgFLA) in patients with early stage carcinoma of prostate. The results will be evaluated by repeated MRI and prostate biopsy. Previous prospective development study demonstrated that FLA may be a viable option for men with low-intermediate risk prostate cancer. The vast majority of patients undergoing this treatment experienced minimal side effects with no peri-operative complications. Over 80% of patients treated with MRgFLA remain on AS and were able to avoid radical therapy at mean follow up duration of 3 years.Read full original descriptionShow less

MRI Guided Focal Laser Ablation of Prostate Cancer

This clinical research study is designed to determine the ability of in bore MRI guided Focal Laser Ablation (MRgFLA) in patients with early stage carcinoma of prostate. The results will be evaluated by repeated MRI and prostate biopsy. Previous prospective development study demonstrated that FLA may be a viable option for men with low-intermediate risk prostate cancer. The vast majority of patients undergoing this treatment experienced minimal side effects with no peri-operative complications. Over 80% of patients treated with MRgFLA remain on AS and were able to avoid radical therapy at mean follow up duration of 3 years.

Inclusion: Men 40-80 years of age; Histologically proven low-intermediate risk prostate carcinoma; (Gleason score ≤ 7, primary grade ≤ 4;); Prostate cancer clinical stage T1c and T2; MR site suspicious for cancer or cancer mapped to one lobe of the prostate using the 3D hybrid TRUS device; Size of MR visible tumor <20mm; Suspicious site on Prostate MRI must coincide with sector positive for cancer on biopsy; Prostate specific antigen (PSA) level <15 ng/mL; IPSS, ICIQ-UI-SF, IIEF complete prior to procedure; Life expectancy of greater than 10 years, based on co-morbidity not related to prostate cancer.

Exclusion: Medically unfit for focal therapy of the prostate; Patients who have received androgen suppression therapy; Patients who have received or are receiving chemotherapy for prostate carcinoma; Patients previously treated with surgery to the prostate (traditional, endoscopic or minimally invasive including HIFU, TUNA, RITA, microwave, cryotherapy or any curative treatment; Patients who have participated in a clinical study and/or received treatment with an investigational treatment and/or product within the past 90 days; Patients who have undergone radiation therapy for prostate cancer or to the pelvis; Any condition, or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient (e.g. significant cardiovascular conditions or allergies); Patients with a history of noncompliance with medical therapy and/or medical recommendations; Chronic or acute prostatitis, neurogenic bladder, urinary tract infection, sphincter abnormalities, or any other symptom that prevents normal micturition; Patients with contraindication to MRI (i.e. pacemaker, hip prosthesis, severe claustrophobia, brain aneurysm clip, allergy to MRI contrast agent); Any condition, or history of illness that, in the opinion of the investigator will confound or increase the patient risk during the study; Patients who are unwilling or unable to give informed consent; Patients who are unwilling or unable to complete the patient self-assessment questionnaires.

ClinicalTrials.gov NCT03650595